Why should you select Luzitin?

• Well-structured company
• Experienced management and scientific team
• Own proprietary innovative technology
• Solid business plan
• Pipeline covering high-value therapeutic fields (oncology and dermatology)
• Reduced time to market (Ready to license-out technology)

Luzitin is open to different investment modalities, from equity sharing to licensing and/or co-development of its therapeutic solutions.

There are three unique opportunities for partnership development of Redaporfin:

1. Redaporfin combined with immune checkpoint inhibitors based on its meaningful in-vivo preclinical immunologic effects to treat melanoma.
2. Redaporfin to treat biliary tract cancer for which EMA has granted Orphan Drug Designation and for which a pivotal study is planned. This provides a further opportunity for fast track status. Application for Orphan Drug Designation by the FDA is planned for later in 2016.
3. Redaporfin to treat head and neck cancer in combination with immune checkpoint inhibitors.

For further information, please contact business@luzitin.pt.